Between Visits Adjusted for Multiple Comparisons in a Generalized Linear
Mixed Model. Analysis is based on the 9 subjects completing the trial;
Data is adjusted for baseline severity (using random intercept in the
mixed model linear regression analysis) and the duration of disease for
each subject (Visit 0 = baseline; Visit 1 =
pre-placebo treatment; Visit 2 = post-placebo/pre-benralizumab
visit; Visits 2-4 = Benralizumab 30 mg s.c. treatment;Visit 5 = 4 week post-Benralizumab visit (determination of
primary efficacy end-point); Visit 6 = 8 week post-benralizumab
follow-up visit (determination of long term efficacy and adverse
events); *primary and exploratory outcomes are shaded (Adj p
<.05).
Table 2. Differences in Relative Eosinophil Counts
(Eos%) Between Visits in CSU Subjects Before and After Treatment with
Benralizumab